Hepatitis B
Adefovir-resistant Hepatitis B Virus Can Remain Susceptible to Tenofovir
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 02 October 2012 00:00
- Written by Liz Highleyman
Tenofovir (Viread) continues to be effective for treating chronic hepatitis B patients who have developed resistance to the related drug adefovir (Hepsera), according to a report in the August 14, 2012, online edition of Antiviral Therapy.
Heavy Alcohol Use Impairs Biochemical Response to Entecavir for Chronic Hepatitis B
- Details
- Category: Approved HBV Drugs
- Published on Friday, 28 September 2012 00:00
- Written by Liz Highleyman
While obese chronic hepatitis B patients and heavy drinkers did not have impaired virological response to entecavir (Baraclude), alcohol use did reduce the likelihood of alanine aminotransferase (ALT) normalization, according to study findings reported in the June 2012 issue of Clinical and Molecular Hepatology. 
Hepatitis B Rates Higher than Expected among Gay Men, Drug Users, Vaccinated Babies
- Details
- Category: HBV Vaccines
- Published on Tuesday, 04 September 2012 00:00
- Written by Liz Highleyman
An unexpectedly high proportion of gay/bisexual men and injection drug users develop chronic hepatitis B rather than clearing the infection, Amsterdam researchers reported in the September 2012 Journal of Hepatology. Other recent studies found that more than one-quarter of children born to mothers with hepatitis B showed evidence of "occult" HBV infection despite vaccination at birth, and that some individuals vaccinated as children may still show evidence of infection as adults.
Tenofovir Is Safe and Effective for Treating Hepatitis B in Adolescents
- Details
- Category: Approved HBV Drugs
- Published on Wednesday, 26 September 2012 00:00
- Written by Liz Highleyman
Teenagers with chronic hepatitis B virus (HBV) infection responded well to 2 years of treatment with tenofovir (Viread) in the first study of the drug in this population, researchers reported in the August 27, 2012, advance online edition of Hepatology.
Tenofovir Hepatitis B Label Update Adds Info on Adolescents, Long-term Data for Adults
- Details
- Category: HBV Treatment
- Published on Thursday, 30 August 2012 00:00
- Written by Press Release
The U.S. Food and Drug Administration (FDA) this week announced that product label information for tenofovir (Viread) has been revised to include further information about treatment of chronic hepatitis B in teenagers and 240-week data for adult patients. 
ICAAC 2012: Switching to Tenofovir in ART Regimen Suppresses Hepatitis B in HIV/HBV Coinfected
- Details
- Category: HBV Epidemiology & Mortality
- Published on Friday, 14 September 2012 00:00
- Written by Liz Highleyman
HIV/HBV coinfected people who substituted tenofovir DF (Viread) for zidovudine (AZT; Retrovir) or abacavir (Ziagen) in their antiretroviral regimen saw a reduction in hepatitis B viral load, despite HBV resistance to lamivudine (3TC; Epivir), according to a poster presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) this week in San Francisco.
Lack of Sleep May Compromise Hepatitis B Vaccine Response
- Details
- Category: HBV Vaccines
- Published on Tuesday, 14 August 2012 00:00
- Written by Liz Highleyman
People who got less than 6 hours of sleep per night showed significantly reduced antibody responses after hepatitis B virus (HBV) vaccination, a finding that may shed light on the well-known association between poor sleep and increased susceptibility to infectious disease, researchers reported in the August 1, 2012, issue of Sleep.
ICAAC 2012: Hepatitis B Vaccine Effective Long-term, but Some Lose Protection after 15 Years
- Details
- Category: HBV Vaccines
- Published on Tuesday, 11 September 2012 00:00
- Written by Liz Highleyman
Nearly all children who received 3 doses of the Engerix-B hepatitis B vaccine achieved protective immunity, but about 20% fell below the protective antibody threshold by year 15 and could benefit from a booster shot, Canadian researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco. 
July 28 Is World Hepatitis Day
- Details
- Category: Hepatitis B
- Published on Friday, 27 July 2012 00:00
- Written by Liz Highleyman
Saturday, July 28, is World Hepatitis Day, an opportunity to raise awareness about life-threatening viral hepatitis. Over years or decades hepatitis B and C can progress to severe liver disease including cirrhosis and liver cancer, and viral hepatitis is a leading indication for liver transplants.
More Articles...
- EASL Publishes Revised Clinical Practice Guidelines for Chronic Hepatitis B
- FDA Will Review New Dynavax Hepatitis B Virus Vaccine
- Researchers Grow Liver Tissue from Pluripotent Stem Cells
- HBV Genotype Affects Hepatitis B Disease Progression and Outcomes
- Researchers Shed Light on how Hepatitis B Virus Causes Liver Cancer
Web Design and Development by